Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

"Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review." Expert Review of Pharmacoeconomics & Outcomes Research, 19(3), pp. 243–244

Acknowledgments

Allie Cichewicz (Evidera) for providing assistance regarding data collection, Evelien Bergrath (Evidera) for providing assistance regarding data collection and development of the letter, and Amy Earley (Evidera) for providing assistance regarding development of the letter.

Declaration of interest

S Deitelzweig is a consultant for Bristol-Myers Squibb Company/Pfizer Inc., Daiichi-Sankyo, Portola, and Boehringer Ingelheim; he also has been on the speakers’ bureau for Bristol-Myers Squibb Company/Pfizer Inc., and Boehringer Ingelheim. GY Lip is a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

The letter to the editor was sponsored by Pfizer Inc. and Bristol-Myers Squibb Company.